QNCX Quince Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 14, 2026
$29.20
· % 处于52周区间
· 高于低点
· 至高点
$15.1052周低点
$910.0052周高点
市值 (MRQ)
$30M
P/E
-0.2
EPS
$-1.68
QNCX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$29.20
市值 (MRQ)
$30M
P/E
-0.2
EPS
$-1.68
ROE
700.5%
负债/权益 (MRQ)
-0.0
52周区间
$15–$910
QNCX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2026年6月30日 | 1-for-20 | 反向 |
| 2026年4月13日 | 1-for-10 | 反向 |
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-1.682021-12-31 → 2025-12-31
自由现金流$-42M2019-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | QNCX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -0.25年均值 ≈-1.9 | ≈-1.9 | · | · | |
| 市净率 (MRQ) | -0.85年均值 ≈0.3 | ≈0.3 | · | · | |
| EV / EBITDA (企业价值 / EBITDA) | -0.6 | · | · | · | |
| 股价/自由现金流 (TTM) | -0.65年均值 ≈-3.2 | ≈-3.2 | · | · | |
| 市现率 (TTM) | -0.65年均值 ≈-3.2 | ≈-3.2 | · | · | |
| 市值/自由现金流 (TTM) | 1.8 | · | · | · | |
| 市净率（有形资产） (MRQ) | -0.85年均值 ≈5.1 | ≈5.1 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | QNCX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -80.8%5年均值 ≈-48.7% | ≈-48.7% | -30.5% | 弱 | |
| ROE | 700.5%5年均值 ≈78.0% | ≈78.0% | -31.1% | 顶尖 | |
| ROIC | 341.4%5年均值 ≈14.7% | ≈14.7% | -78.9% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | QNCX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | -0.0 | · | 0.0 | 持平 | |
| 流动比率 (MRQ) | 14.55年均值 ≈10.6 | ≈10.6 | 2.1 | 流动性强 | |
| Quick Ratio (速动比率) | 0.15年均值 ≈10.1 | ≈10.1 | 1.0 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-18.9%
下次报告
十一月 10, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 14, 2026 | $-12.31 | $-18.24 | 32.5% |
| 2026年3月31日 | 五月 11, 2026 | $57.60 | $-52.22 | 210.3% |
| 2025年12月31日 | $-142.00 | $-38.52 | -268.7% | |
| 2025年9月30日 | $-50.00 | $-44.15 | -13.3% | |
| 2025年6月30日 | $-46.00 | $-51.34 | 10.4% | |
| 2025年3月31日 | $-3.40 | $-2.32 | -46.5% | |
| 2024年12月31日 | $-0.28 | $-0.18 | -56.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $35M | $19M | $9M | $25M | $61M | $61M | $30M | $10M | |
| SG&A Expense | $15M | $18M | $18M | $26M | $30M | $18M | $9M | $2M | |
| Operating Expenses | $58M | $57M | $35M | $52M | $90M | $79M | $39M | $12M | |
| Operating Income | $-58M | $-57M | $-35M | $-52M | $-90M | $-79M | $-39M | $-12M | |
| Interest Expense | · | · | · | · | · | · | · | $957.0K | |
| Interest Income | $1M | $3M | $3M | $1M | $620.0K | $2M | $2M | $806.0K | |
| Other Non-op | $486.0K | $-676.0K | $-102.0K | $-997.0K | $-247.0K | $0 | $0 | · | |
| Pretax Income | $-81M | $-57M | $-32M | $-52M | $-90M | $-77M | $-37M | · | |
| Income Tax | $3M | $87.0K | $-197.0K | $-284.0K | $0 | $0 | $0 | $0 | |
| Net Income | $-84M | $-57M | $-31M | $-52M | $-90M | $-77M | $-37M | $-12M | |
| EPS (Basic) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · | |
| EPS (Diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · | |
| Shares (Basic) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · | |
| Shares (Diluted) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · | |
| EBITDA | $-58M | $-57M | $-35M | $-52M | $-90M | $-79M | $-39M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6M | $6M | $75M | $41M | $29M | $134M | $51M | $25M | |
| Short-term Investments | $12M | · | · | · | · | · | · | · | |
| Receivables | · | · | · | $0 | · | · | · | · | |
| Prepaid Expense | $5M | $3M | $2M | $4M | $5M | $4M | $6M | $868.0K | |
| Other Current Assets | $54.0K | $84.0K | $81.0K | $276.0K | $367.0K | $694.0K | $688.0K | $68.0K | |
| Current Assets | $23M | $44M | $77M | $94M | $112M | $138M | $106M | $73M | |
| PP&E (Net) | $595.0K | $315.0K | $234.0K | $393.0K | $263.0K | $427.0K | $709.0K | $283.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | $378.0K | |
| Accum. Depreciation | $844.0K | $639.0K | $507.0K | $185.0K | $959.0K | $615.0K | $283.0K | $95.0K | |
| Goodwill | · | $0 | $18M | $0 | $0 | · | · | · | |
| Intangibles | $68M | $60M | $64M | $6M | $0 | · | · | · | |
| Other Non-current Assets | $2M | $10M | $9M | $0 | $194.0K | $39.0K | $217.0K | $10.0K | |
| Total Assets | $94M | $114M | $168M | $104M | $133M | $189M | $124M | $73M | |
| Accounts Payable | $2M | $3M | $2M | $570.0K | $5M | $4M | $3M | $495.0K | |
| Accrued Liabilities | $11M | $4M | $3M | $2M | $9M | $13M | $6M | $962.0K | |
| Current Liabilities | $43M | $7M | $10M | $3M | $14M | $17M | $9M | $1M | |
| Capital Leases | $330.0K | $394.0K | $321.0K | $0 | $420.0K | $208.0K | · | · | |
| Deferred Tax | $0 | $5M | $5M | $248.0K | $0 | · | · | · | |
| Other Non-current Liabilities | $2M | $685.0K | $587.0K | $0 | · | · | · | · | |
| Total Liabilities | $129M | $84M | $83M | $3M | $15M | $17M | $9M | $1M | |
| Long-term Debt | $0 | $14M | $13M | $0 | · | · | · | · | |
| Total Debt | $18M | · | · | · | · | · | · | · | |
| Common Stock | $0 | $44.0K | $43.0K | $36.0K | $30.0K | $29.0K | $27.0K | $3.0K | |
| Paid-in Capital | $419M | $407M | · | · | · | · | · | · | |
| Retained Earnings | $-460M | $-376M | $-320M | $-288M | $-237M | $-147M | $-70M | $-33M | |
| AOCI | $6M | $-35.0K | $3M | $-289.0K | $-79.0K | $313.0K | $60.0K | $-49.0K | |
| Stockholders' Equity | $-36M | $30M | $85M | $101M | $119M | $172M | $115M | $-33M | |
| Liabilities + Equity | $94M | $114M | $168M | $104M | $133M | $189M | $124M | $73M | |
| Shares Outstanding | 278,627 | 220,009 | 42,973,215 | 36,136,480 | 30,074,412 | 29,543,222 | 26,869,413 | 3,412,366 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $142.0K | $186.0K | $322.0K | $204.0K | $344.0K | $332.0K | $188.0K | $51.0K | |
| Stock-based Comp | $5M | $5M | $5M | $17M | $30M | $14M | $2M | $155.0K | |
| Deferred Tax | $-6M | $-45.0K | $-258.0K | $284.0K | · | · | · | · | |
| Operating Cash Flow | $-41M | $-32M | $-18M | $-44M | $-63M | $-51M | $-33M | $-12M | |
| CapEx | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K | $52.0K | $55.0K | $212.0K | |
| Investing Cash Flow | $23M | $22M | $-6M | $18M | $59M | $-52M | $-18M | $-47M | |
| Stock Issued | · | · | $0 | $608.0K | $0 | · | · | · | |
| Net Stock Activity | · | · | $0 | $608.0K | · | · | · | · | |
| Financing Cash Flow | $18M | $-5M | $143.0K | $707.0K | $7M | $119M | $77M | $76M | |
| Net Change in Cash | $-403.0K | $-15M | $-24M | $-25M | $3M | $16M | $26M | · | |
| Free Cash Flow | $-42M | $-32M | $-18M | $-44M | $-63M | $-51M | $-33M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROA | -80.8% | -40.2% | -23.1% | -43.6% | -55.8% | -49.0% | -37.5% | · | |
| ROE | 700.5% | -151.4% | -37.3% | -50.4% | -71.6% | -42.7% | -30.5% | · | |
| ROIC | 341.4% | -190.3% | -40.9% | -51.4% | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.5 | 6.1 | 8.1 | 30.5 | 7.9 | 8.1 | 11.9 | · | |
| Quick Ratio | 0.1 | 5.6 | 7.8 | 29.4 | 7.5 | 7.9 | 5.8 | · | |
| Debt / Equity | -0.5 | · | · | · | · | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.64 | $0.69 | $1.98 | $2.78 | $3.94 | $5.83 | $4.30 | · | |
| Cash Flow / Share | $-0.83 | $-0.74 | $-0.49 | $-1.31 | · | · | · | · | |
| Cash / Share | $0.10 | $0.93 | $1.75 | $2.50 | $3.55 | $4.53 | $1.91 | · | |
| EPS (TTM) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-84M | $-57M | $-31M | $-52M | $-90M | $-77M | $-37M | · | |
| Market Cap | $187M | $82M | $45M | $23M | $380M | $821M | $1.51B | · | |
| Enterprise Value | $199M | · | · | · | · | · | · | · | |
| P/E | -2.0 | -1.4 | -1.2 | -0.4 | -4.2 | · | · | · | |
| P/B | -5.2 | 2.7 | 0.5 | 0.2 | 3.2 | 4.8 | 13.1 | · | |
| P / Tangible Book | · | · | 11.9 | 0.2 | 3.2 | 4.8 | · | · | |
| P / Cash Flow | -4.5 | -2.6 | -2.5 | -0.5 | -6.0 | -16.1 | -45.3 | · | |
| P / FCF | -4.5 | -2.6 | -2.4 | -0.5 | -6.0 | -16.1 | -45.3 | · | |
| EV / EBITDA | -3.4 | · | · | · | · | · | · | · | |
| EV / FCF | -4.8 | · | · | · | · | · | · | · | |
| Earnings Yield | -50.1% | -70.0% | -80.0% | -241.8% | -24.0% | · | · | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $5M | $7M | $13M | $8M | $7M | $8M | $6M | $5M | $4M | $4M | $3M | $1M | $1M | $3M | $3M | $2M | |
| SG&A Expense | $17M | $4M | $4M | $3M | $3M | $5M | $4M | $4M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $80M | $15M | $19M | $13M | $10M | $15M | $12M | $6M | $28M | $11M | $10M | $6M | $6M | $13M | $6M | $8M | |
| Operating Income | $-80M | $-15M | $-19M | $-13M | $-10M | $-15M | $-12M | $-6M | $-28M | $-11M | $-10M | $-6M | $-6M | $-13M | $-6M | $-8M | |
| Interest Income | $584.0K | $160.0K | $227.0K | $300.0K | $311.0K | $406.0K | $536.0K | $683.0K | $823.0K | $887.0K | $1M | $959.0K | $805.0K | $700.0K | $536.0K | $315.0K | |
| Other Non-op | $152.0K | $2M | $660.0K | $-58.0K | $-29.0K | $-87.0K | $-518.0K | $150.0K | $91.0K | $-399.0K | $467.0K | $-216.0K | $-107.0K | $-246.0K | $204.0K | $-616.0K | |
| Pretax Income | · | · | · | · | · | $-15M | · | · | · | $-11M | · | · | · | · | · | · | |
| Income Tax | $75.0K | $-5M | $3M | $-46.0K | $67.0K | $47.0K | $7.0K | $13.0K | $36.0K | $31.0K | $51.0K | $0 | $0 | $-248.0K | $0 | $0 | |
| Net Income | $-75M | $36M | $-39M | $-13M | $-16M | $-15M | $-12M | $-5M | $-28M | $-11M | $-9M | $-5M | $-5M | $-12M | $-6M | $-8M | |
| EPS (Basic) | $-12.31 | $3.60 | $-0.75 | $-0.25 | $-68.75 | $-3.42 | $-0.28 | $-0.13 | $-0.64 | $-0.26 | $-0.21 | $-0.15 | $-0.14 | $-0.34 | $-0.09 | $-0.22 | |
| EPS (Diluted) | $-12.31 | $2.88 | $-0.75 | $-0.25 | $-68.75 | $-3.42 | $-0.28 | $-0.13 | $-0.64 | $-0.26 | $-0.21 | $-0.15 | $-0.14 | $-0.34 | $-0.09 | $-0.22 | |
| Shares (Basic) | 6,132,845 | 9,120,267 | · | 53,951,371 | 233,431 | 4,394,119 | · | 43,164,136 | 43,096,374 | 43,010,212 | · | 36,073,040 | 35,917,592 | 35,855,200 | · | 35,612,749 | |
| Shares (Diluted) | 6,132,845 | 9,190,354 | · | 53,951,371 | 233,431 | 4,394,119 | · | 43,164,136 | 43,096,374 | 43,010,212 | · | 36,073,040 | 35,917,592 | 35,855,200 | · | 35,612,749 | |
| EBITDA | $-80M | $-15M | · | $-13M | $-10M | $-15M | · | $-6M | $-28M | $-11M | · | $-6M | $-6M | $-13M | · | $-8M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $116M | $18M | $6M | $6M | $17M | $8M | $6M | $48M | $59M | $68M | · | $21M | $21M | $42M | · | $22M | |
| Short-term Investments | $0 | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | $500.0K | · | · | · | · | |
| Prepaid Expense | $7M | $7M | $5M | $3M | $3M | $2M | $3M | $4M | $4M | $3M | $2M | $1M | $983.0K | $2M | $4M | $4M | |
| Other Current Assets | $393.0K | $24.0K | $54.0K | $96.0K | $55.0K | $32.0K | $84.0K | $55.0K | $79.0K | $48.0K | $81.0K | $92.0K | $143.0K | $179.0K | $276.0K | $336.0K | |
| Current Assets | $123M | $26M | $23M | $29M | $37M | $34M | $44M | $52M | $63M | $70M | $77M | $85M | $89M | $92M | $94M | $98M | |
| PP&E (Net) | $506.0K | $550.0K | $595.0K | $616.0K | $573.0K | $448.0K | $315.0K | $208.0K | $246.0K | $234.0K | $234.0K | $5.0K | $6.0K | $6.0K | $393.0K | $375.0K | |
| Accum. Depreciation | $882.0K | $856.0K | $844.0K | $807.0K | $777.0K | $691.0K | $639.0K | $667.0K | $566.0K | $530.0K | $507.0K | $13.0K | $12.0K | $12.0K | $185.0K | $159.0K | |
| Goodwill | · | · | · | $0 | · | · | $0 | $0 | $0 | $17M | $18M | $0 | $0 | $0 | $0 | $0 | |
| Intangibles | $0 | $0 | $68M | $68M | $68M | $62M | $60M | $65M | $62M | $62M | $64M | $0 | $0 | $0 | $6M | $6M | |
| Other Non-current Assets | $78.0K | $78.0K | $2M | $12M | $11M | $10M | $10M | $10M | $9M | $8M | $9M | · | · | · | $0 | $17.0K | |
| Total Assets | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M | $135M | $159M | $168M | $85M | $89M | $93M | $104M | $110M | |
| Accounts Payable | $5M | $5M | $2M | $3M | $2M | $3M | $3M | $2M | $2M | $2M | $2M | $409.0K | $353.0K | $2M | $570.0K | $1M | |
| Accrued Liabilities | $4M | $3M | $11M | $5M | $6M | $5M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $1M | $2M | $4M | |
| Current Liabilities | $8M | $9M | $43M | $26M | $7M | $8M | $7M | $5M | $10M | $10M | $10M | $2M | $2M | $3M | $3M | $5M | |
| Capital Leases | $0 | $293.0K | $330.0K | $359.0K | $387.0K | $383.0K | $394.0K | $450.0K | $453.0K | $480.0K | $321.0K | · | · | · | $0 | $34.0K | |
| Deferred Tax | · | · | $0 | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $5M | $0 | $0 | $0 | $248.0K | $248.0K | |
| Other Non-current Liabilities | $716.0K | $1M | $2M | $778.0K | $745.0K | $716.0K | $685.0K | $643.0K | $609.0K | $599.0K | $587.0K | · | · | · | $0 | · | |
| Total Liabilities | $16M | $11M | $129M | $109M | $105M | $89M | $84M | $82M | $88M | $85M | $83M | $2M | $2M | $3M | $3M | $5M | |
| Long-term Debt | · | · | $0 | $0 | $17M | $15M | $14M | $15M | $14M | $14M | $13M | · | · | · | $0 | · | |
| Total Debt | $0 | $0 | · | $18M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $1.0K | $14.0K | $55.0K | $54.0K | $53.0K | $44.0K | $44.0K | $43.0K | $43.0K | $43.0K | $43.0K | $36.0K | $36.0K | $36.0K | $36.0K | $36.0K | |
| Paid-in Capital | $460M | $436M | $419M | $416M | $413M | $408M | $407M | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-500M | $-425M | $-460M | $-421M | $-408M | $-392M | $-376M | $-364M | $-359M | $-331M | $-320M | $-311M | $-305M | $-301M | $-288M | $-283M | |
| AOCI | $4M | $5M | $6M | $6M | $6M | $2M | $-35.0K | $3M | $1M | $2M | $3M | $516.0K | $257.0K | $38.0K | $-289.0K | $-253.0K | |
| Stockholders' Equity | $-35M | $16M | $-36M | $1M | $12M | $19M | $30M | $45M | $47M | $74M | $85M | $83M | $87M | $90M | $101M | $105M | |
| Liabilities + Equity | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M | $135M | $159M | $168M | $85M | $89M | $93M | $104M | $110M | |
| Shares Outstanding | 1,017,063 | 13,790,794 | 55,725,291 | 54,494,965 | 53,624,180 | 44,089,142 | 44,001,643 | 43,276,606 | 43,276,606 | 43,215,233 | 42,973,215 | 36,343,632 | 36,327,995 | 36,278,433 | 36,136,480 | 36,130,306 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $41.0K | $36.0K | $39.0K | $36.0K | $35.0K | $32.0K | $16.0K | $86.0K | $44.0K | $40.0K | $304.0K | $0 | $1.0K | $17.0K | $42.0K | $40.0K | |
| Stock-based Comp | $12M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $694.0K | |
| Operating Cash Flow | $-19M | $-8M | $-10M | $-10M | $-11M | $-10M | $-8M | $-7M | $-9M | $-8M | $-6M | $-5M | $-4M | $-4M | $-6M | $-7M | |
| CapEx | $0 | $0 | $4.0K | $74.0K | $126.0K | $148.0K | $133.0K | $46.0K | $39.0K | $39.0K | $24.0K | $0 | $0 | $136.0K | $78.0K | $50.0K | |
| Investing Cash Flow | $8M | $12M | $8M | $-2M | $6M | $11M | $11M | $7M | $-5M | $9M | $5M | $4M | $-20M | $6M | $19M | $-9M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $109M | $9M | $2M | $1M | $14M | $87.0K | $0 | $-5M | $35.0K | $190.0K | $57.0K | $10.0K | $26.0K | $50.0K | $-18.0K | $-5.0K | |
| Net Change in Cash | $98M | $12M | $-643.0K | $-10M | $9M | $2M | $4M | $-5M | $-14M | $1M | $-880.0K | $-1M | $-24M | $2M | $13M | $-15M | |
| Free Cash Flow | · | $-8M | · | · | · | $-10M | · | · | · | $-8M | · | · | · | $-4M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -62.6% | 53.7% | · | -11.4% | -12.7% | -11.3% | · | -5.2% | -24.8% | -8.8% | · | -5.5% | -4.7% | -11.7% | · | -6.2% | |
| ROE | 640.0% | 209.7% | · | -58.5% | -54.7% | -32.4% | · | -8.6% | -41.4% | -13.6% | · | -5.7% | -4.9% | -12.5% | · | -6.7% | |
| ROIC | · | · | · | · | · | -80.2% | · | · | · | · | · | · | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.5 | 2.9 | · | 1.1 | 5.0 | 4.0 | · | 9.5 | 6.1 | 7.2 | · | 37.8 | 45.4 | 29.7 | · | 19.9 | |
| Quick Ratio | 13.6 | 2.1 | · | 0.2 | 2.3 | 0.9 | · | 8.8 | 5.8 | 6.9 | · | 9.5 | 10.6 | 13.6 | · | 4.4 | |
| Debt / Equity | 0.0 | 0.0 | · | 16.5 | · | · | · | · | · | · | · | · | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-34.73 | $1.14 | · | $0.02 | $0.22 | $0.42 | · | $1.04 | $1.09 | $1.72 | · | $2.29 | $2.39 | $2.49 | · | $2.89 | |
| Cash Flow / Share | · | $-0.83 | · | · | · | $-0.22 | · | · | · | $-0.19 | · | · | · | $-0.10 | · | · | |
| Cash / Share | $114.04 | $1.32 | · | $0.12 | $0.31 | $0.18 | · | $1.10 | $1.37 | $1.57 | · | $0.57 | $0.57 | $1.17 | · | $0.60 | |
| EPS (TTM) | $-10.43 | $-66.87 | · | $-72.70 | $-72.58 | $-4.47 | · | $-1.24 | $-1.26 | $-0.76 | · | $-0.72 | $-0.79 | $-1.16 | · | $-2.23 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-92M | $-33M | · | $-57M | $-49M | $-61M | · | $-53M | $-53M | $-30M | · | $-28M | $-31M | $-42M | · | $-70M | |
| Market Cap | $19M | $1M | · | $89M | $88M | $59M | · | $34M | $32M | $46M | · | $41M | $55M | $57M | · | $48M | |
| Enterprise Value | $-97M | $-17M | · | $100M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -1.7 | -0.0 | · | -0.0 | -0.0 | -0.3 | · | -0.6 | -0.6 | -1.4 | · | -1.6 | -1.9 | -1.3 | · | -0.6 | |
| P/B | -0.5 | 0.1 | · | 83.9 | 7.5 | 3.2 | · | 0.7 | 0.7 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | |
| P / Tangible Book | · | 0.1 | · | · | · | · | · | · | · | · | · | 0.5 | 0.6 | 0.6 | · | 0.5 | |
| P / Cash Flow | · | -0.2 | · | · | · | -6.1 | · | · | · | -5.5 | · | · | · | -15.9 | · | · | |
| Earnings Yield | -57.3% | -66207.9% | · | -4460.1% | -4398.8% | -336.1% | · | -159.8% | -168.0% | -71.7% | · | -64.3% | -52.5% | -74.4% | · | -167.7% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 净收入 | $-84M | $-57M | $-31M | $-52M | $-90M |
| 稀释后每股收益 (EPS) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -0.5 | · | · | · | · |
| 流动比率 | 0.5 | 6.1 | 8.1 | 30.5 | 7.9 |
| 速动比率 | 0.1 | 5.6 | 7.8 | 29.4 | 7.5 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-42M | $-32M | $-18M | $-44M | $-63M |
机构持有人 (13F) 2 家申报者 · $7.1M 总计 · 截至 2025年12月31日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
2
持有价值
$7.1M
新仓位
15
已退出持仓
35
机构活动 — Q1 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 15 (-11 与上一季度对比) | 35 (+31 与上一季度对比) | 8 (-13 与上一季度对比) | 12 (+7 与上一季度对比) | -5.2M |
与Q4 2025对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6981450 | 2084015 | 98.72% | 股份 |
| TWO SIGMA ADVISERS, LP | $90785 | 27100 | 1.28% | 股份 |
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| David A. Lamond | 2024年11月13日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 24 位内幕人士 · 14 位高管 · 14 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Dirk Thye | CEO and CMO | 2026年1月23日 A | 739885 | 0 | 0 | $0 |
| Christopher P. Lowe | Interim CEO, COO & CFO | 2022年3月3日 A | 265000 | 0 | 0 | $0 |
| Casey Lynch | Chief Executive Officer | 2022年1月3日 A | 109895 | 0 | 0 | $0 |
| Charles S. Ryan | President | 2026年1月23日 A | 130009 | 0 | 0 | $0 |
| Brendan Hannah | CBO, COO & CCO | 2026年1月23日 A | 361827 | 0 | 0 | $0 |
| Brigette Roberts | Chief Corp. Affairs Officer | 2026年5月18日 A | · | 0 | 0 | $0 |
| Guenter Janhofer | Chief Scientific Officer | 2023年10月23日 A | · | 0 | 0 | $0 |
| Ted Monohon | Chief Accounting Officer & VP | 2023年3月6日 S | 27440 | 0 | 0 | $0 |
| Karen L. Smith | Chief Medical Officer | 2023年2月1日 A | 194690 | 0 | 0 | $0 |
| Leslie Holsinger | EVP, Preclinical Development | 2022年6月6日 F | 148080 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | Chief Legal & Adm. Officer | 2022年6月6日 S | 122500 | 0 | 0 | $0 |
| Michael J. Detke | Chief Medical Officer | 2022年3月3日 A | 140000 | 0 | 0 | $0 |
| Stephen S. Dominy | Chief Scientific Officer | 2022年1月3日 A | 1217086 | 0 | 0 | $0 |
| Kristen Gafric | SVP, Legal & Administration | 2020年2月6日 A | · | 0 | 0 | $0 |
| David Lamond | 董事 | 2026年6月11日 A | 2347545 | 0 | 0 | $0 |
| Christopher J. Senner | 董事 | 2026年6月11日 A | · | 0 | 0 | $0 |
| June Bray | 董事 | 2026年1月2日 A | · | 0 | 0 | $0 |
| Margaret Mcloughlin | 董事 | 2026年1月2日 A | 8000 | 0 | 0 | $0 |
| Luca Benatti | 董事 | 2025年12月26日 S | 39179 | 0 | 1 | $-173500 |
| Rajiv Patni | 董事 | 2025年6月4日 A | · | 0 | 0 | $0 |
| Una S Ryan | 董事 | 2025年6月4日 A | 2875 | 0 | 0 | $0 |
| Philip S Low | 董事 | 2022年5月19日 A | 63974 | 0 | 0 | $0 |
| Marwan Sabbagh | 董事 | 2022年3月14日 A | · | 0 | 0 | $0 |
| Kevin Young | 董事 | 2020年6月8日 A | 30000 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 1 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0.00% | 12044 SH | 2026年8月19日 | 每日 |
QNCX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 13 位分析师
买入
中位数目标
$70.00
+139.7%
4 30.8%
强烈买入
5 38.5%
买入
4 30.8%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
7 位分析师 · 2026-10-04平均目标 $75.43 +158.3%
← 低于所有目标
当前价格 $29.20
最低$65.00
平均值$75.43
最高$98.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 14, 2026 申报